Compare Globus Medical Inc. Class A Common Stock (GMED) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Meta Platforms Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Meta Platforms Inc trades at $730.17 (market cap $1.94T). The key difference: Meta Platforms Inc is far larger — about 189.3× Globus Medical Inc. Class A Common Stock's market cap, and Meta Platforms Inc pays a 0.28% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Meta Platforms Inc for 128 Days on average.
| GMED | META | |
|---|---|---|
Market Cap | $10.25B | $1.94T |
Volume | 1,108,124 | 22,627,792 |
Sector | Health | Media |
52-Week High | $96.82 | $777.59 |
52-Week Low | $58.33 | $525.72 |
Typical Hold Time | 0 Days | 128 Days |
Enterprise Value | $9.76B | $1.96T |
Dividend Yield | — | 0.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Meta Platforms (META) trades at $737.54, down 0.73% on the day, with strong bullish technical signals from moving averages and ADX indicators. The company demonstrates robust fundamentals with $201B revenue in 2025, 29.8% net margin, and consistent earnings beats in recent quarters. Recent AI developments including Muse Spark launch and a $21B CoreWeave deal highlight growth initiatives.
Wall Street maintains strong bullish sentiment with 80% buy ratings and $802.80 consensus target, representing 9% upside. Key risks include ongoing youth addiction litigation in Massachusetts and elevated capital expenditures for AI infrastructure. The stock presents growth potential through AI monetization but faces regulatory and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
